Associated Papers
Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age-Related Studies in Thai Adults and Cross-Population Comparisons.
Srimatimanon T et al.
Clinical and Translational Science, 2026
Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
Magadmi R et al.
Pharmaceuticals (basel, Switzerland), 2025
Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.
Tipnoppanon S et al.
Clinical and Translational Science, 2025
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia.
Bai J et al.
Frontiers in Genetics, 2019
Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine.
Liu R et al.
Scientific Reports, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
Emami Riedmaier A et al.
Journal of Clinical Pharmacology, 2016
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Hasunuma T et al.
British Journal of Clinical Pharmacology, 2016
Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
Medhasi S et al.
Frontiers in Pharmacology, 2016
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM et al.
Methods in Molecular Biology (clifton, N.j.), 2014
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.
Mattie M et al.
Neoplasia (new York, N.y.), 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
de Graan AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA et al.
Expert Opinion on Pharmacotherapy, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.
Sanna S et al.
Human Molecular Genetics, 2009
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.
Mwinyi J et al.
European Journal of Clinical Pharmacology, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
Maeda K et al.
Drug Metabolism and Pharmacokinetics, 2008
OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
Zhang W et al.
Clinical and Experimental Pharmacology & Physiology, 2007
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007
Genetic variation in thyroid hormone transporters.
van der Deure WM et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2007
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
Tirona RG et al.
The Journal of Biological Chemistry, 2001
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.
Anabtawi N et al.
Expert Opinion on Drug Metabolism & Toxicology, 0